SAPHNELO

Saphnelo is indicated for the treatment of moderate to severe systemic lupus erythematosus (SLE) in adults. It is recommended to be used in conjunction with other SLE treatments, which may include prednisone (Rayos) and other steroids.

Methotrexate, also known as Rheumatrex®, Mycophenolate mofetil, also known as Cellcept®, Azathioprine, also known as Imuran®, Cyclophosphamide, also known as Cytoxan®, and Voclosporin, also known as Lupkynis®.

In 2021, the FDA granted approval to anifrolumab for the treatment of moderate to severe systemic lupus erythematosus in adult patients.

Anifrolumab-fnia, also known as Saphnelo, is a recently approved intravenous medication for Lupus by the FDA in 2021. This fully human monoclonal antibody functions by attaching to specific cytokines called Type I interferons, which play a role in the inflammatory process.

Saphnelo is a human monoclonal antibody that works as a type 1 interferon (INF) receptor antagonist. It blocks the IFNAR receptor, a key protein in the immune system that amplifies signals from type I interferons, acting as a transmitter.

The frequency of Saphnelo administration is typically once every 4 weeks, although your doctor will determine the appropriate dosage based on your individual response. While this medication helps manage SLE, it does not provide a cure.

No, your SAPHNELO infusion treatment is not chemotherapy. SAPHNELO is a biologic therapy that contains anifrolumab-fnia, a monoclonal antibody. It targets type 1 interferon (IFN-1) activity, which is involved in the way lupus affects your body.

You may experience headache, nausea, vomiting, dizziness, or tiredness while taking this medication. If any of these symptoms persist or worsen, please inform your doctor or pharmacist immediately.

Saphnelo (anifrolumab) belongs to the selective immunosuppressants drug class and is typically prescribed for Lupus. The price of Saphnelo intravenous solution (300 mg/2 mL) is approximately $5,277 for a 2 milliliter supply, but may vary depending on the pharmacy.

The suggested amount of SAPHNELO to be taken is 300 mg every 4 weeks. It will take approximately 30 minutes to administer the complete dose of SAPHNELO. Your healthcare professionals will provide guidance on the necessary time before and after your infusion.

In 2021, the FDA granted approval to Voclosporin for the treatment of active lupus nephritis in adult patients. This medication is administered alongside other drugs such as hydroxychloroquine, glucocorticoids, and mycophenolate mofetil.

The most frequently reported adverse effects include headache, nausea, vomiting, fatigue, weakness, and dizziness (associated with infusion). Other possible side effects may include rash, redness, itching, or swelling of the skin at the site of SAPHNELO administration (indicative of hypersensitivity).

Doxorubicin, a potent chemotherapy option, effectively targets various cancers by disrupting the life cycle of cancer cells and inhibiting their ability to reproduce.

Although there is currently no cure for lupus, various treatments are available to alleviate symptoms and improve overall well-being. The specific treatment plan will be tailored to address individual symptoms and requirements. The primary objectives of treatment are to minimize the occurrence of flares.

Your dose of Saphnelo will be administered by a healthcare professional at your doctor’s office, hospital, or infusion suite. In certain situations, a healthcare professional may be able to visit your home to administer the medication. The infusion process for Saphnelo typically lasts around 30 minutes.

Benlysta has been on the market for a longer period of time compared to Saphnelo, and clinical trials have demonstrated its safety and effectiveness when used for at least 13 years. IV Benlysta is generally less expensive than Saphnelo. Saphnelo has been associated with an increased risk of developing shingles. Both medications are not recommended for use during pregnancy or while breastfeeding.

Prednisone is the most frequently prescribed steroid for treating lupus. If you have liver issues, your doctor may suggest alternative steroids such as prednisolone or methylprednisolone (Medrol®). Steroids are typically taken in pill form by most individuals.

Most rheumatologists recommend that all people with lupus take hydroxychloroquine for the long term as it has been found to reduce the likelihood of lupus flares. Additionally, the side effects of anti-malarial medications are rare.

While the product information for Benlysta does not mention weight gain as a potential side effect, a phase IV clinical study examined data from 14,100 individuals who had used Benlysta and found that 2.87% of them (404 people) experienced weight gain as a side effect.

The full dose of SAPHNELO is administered through an infusion that typically lasts for approximately 30 minutes. It is recommended to receive SAPHNELO once every 4 weeks. In the event that you miss an appointment, it is important to contact your healthcare provider promptly in order to reschedule.

Furthermore, Saphnelo-treated patients experienced a higher proportion of time in remission (17.2% vs. 8.3%; 95% CI 3.2-14.5; p=0.0022) and had a greater likelihood of maintaining remission for three or more visits compared to those receiving standard therapy alone (30.2% vs. 17.2%; 95% CI 1.2-3.6; p=0.0127).

New research has discovered that telitacicept, a biologic therapy, is a promising and safe treatment option for lupus, particularly for lupus nephritis. The study found that telitacicept was effective in managing the symptoms of lupus and was well tolerated by patients.

Infusion reactions may occur during or shortly after the infusion of SAPHNELO. Symptoms can include headache, nausea, vomiting, fatigue, and dizziness. It is important to note that these are not the only possible side effects of the medication. If you experience any side effects, it is recommended to contact your doctor for medical advice.

Belimumab has received FDA approval for the treatment of lupus, regardless of whether or not the patient has kidney involvement. Additionally, a new oral medication called voclosporin, classified as a calcineurin inhibitor, has emerged as another option for lupus treatment.

The price of a 2 milliliter supply of Saphnelo intravenous solution (fnia 300 mg/2 mL) can vary, but it is typically around $5,277, depending on the pharmacy you choose.

Drug-induced lupus has a positive outlook with lower rates of illness and death compared to systemic lupus erythematosus (SLE). In the majority of cases, DIL clears up within a few weeks after stopping the medication, and only a small number of patients require treatment for several months. Severe illness is rare.

Please consult your doctor immediately if you experience any of the following side effects: anxiety, chest pain, or mood and behavior changes.

The full dose of SAPHNELO is administered through an infusion that typically lasts for approximately 30 minutes. It is recommended to receive SAPHNELO once every 4 weeks. In the event that you miss an appointment, it is important to contact your healthcare provider promptly in order to reschedule.

The two most common medications for lupus are RITUXAN® (rituximab) and BENLYSTA (belimumab).

Symptoms of drug-induced lupus can include muscle and joint pain, weight loss, and fever. While this condition can be life-threatening, it is completely reversible once the responsible drug is discontinued.

Calcineurin inhibitors can be used as second-line treatments for induction or maintenance therapy, particularly in cases of membranous lupus nephritis, podocytopathy, or proliferative disease with nephrotic syndrome that does not respond to standard-of-care treatment within 3-6 months. In cases that do not respond to other treatments, calcineurin inhibitors may be used in combination with other therapies.

Azathioprine, cyclophosphamide, and methotrexate are immunosuppressants that decrease immune system activity to alleviate lupus symptoms. Azathioprine is specifically prescribed for lupus treatment and is also utilized for other immune disorders and organ transplants.